Dalcor Pharmaceuticals, of Montreal, appointed David G. Kallend chief scientific officer.
Harpoon Therapeutics Inc., of South San Francisco, appointed Joanne Viney to its board.
JSC Olainfarm, of Olaine, Latvia, elected Zane Kotāne to its management board.
Lodo Therapeutics Corp., of New York, appointed Steve Colletti chief scientific officer and Brad Hover vice president, discovery research and platform technology. It also named Sean Brady, Jon Clardy, Benjamin Cravatt, Peter Karp, Michael Pirrung and Christine Schuberth-Wagner to its scientific advisory board, with Brady serving as chair.
Novavax Inc., of Gaithersburg, Md., appointed Frank Czworka senior vice president, global sales and Brian Webb senior vice president, manufacturing.
Noxxon Pharma NV, of Berlin, appointed C. A. Oscar Izeboud to its supervisory board.
Nugenerex Immuno-Oncology, a subsidiary of Generex Biotechnology Corp., of Miramar, Fla., appointed Joseph Moscato (CEO and president), Anthony Crisci (corporate counsel and chief legal officer), Richard Purcell (executive vice president of R&D), Craig Eagle, Marvin Hausman, Carol Nacy, Gail Eckhardt, Thomas Leonard and Brian T. McGee to its board. Moscato will serve as chair.
Rexgenero Ltd., of London, appointed Gilbert Wagener senior vice president and chief medical officer.
Theravance Biopharma Inc., of Dublin, appointed Deepika R. Pakianathan to its board.